HRP20190995T1 - LIJEČENJE HBV-a - Google Patents
LIJEČENJE HBV-a Download PDFInfo
- Publication number
- HRP20190995T1 HRP20190995T1 HRP20190995TT HRP20190995T HRP20190995T1 HR P20190995 T1 HRP20190995 T1 HR P20190995T1 HR P20190995T T HRP20190995T T HR P20190995TT HR P20190995 T HRP20190995 T HR P20190995T HR P20190995 T1 HRP20190995 T1 HR P20190995T1
- Authority
- HR
- Croatia
- Prior art keywords
- ddrnai
- sequence
- effector
- sequences
- agent
- Prior art date
Links
- 239000012636 effector Substances 0.000 claims 21
- 239000003795 chemical substances by application Substances 0.000 claims 20
- 239000002773 nucleotide Substances 0.000 claims 9
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 230000000295 complement effect Effects 0.000 claims 7
- 241000700721 Hepatitis B virus Species 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 claims 1
- 108700024845 Hepatitis B virus P Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Control Of Eletrric Generators (AREA)
Claims (15)
1. Agens RNK interferencije usmjerene sa DNK (ddRNKi) za inhibiciju ekspresije jedne ili više cilјnih sekvenci u jednom ili u više gena virusa hepatitisa B (HBV), ddRNKi agens koji sadrži, u smjeru 5’ do 3’:
prvu efektorsku sekvencu dužine od najmanje 17 nukleotida;
drugu efektorsku sekvencu dužine od najmanje 17 nukleotida;
sekvencu komplementa druge efektorske sekvence; i
sekvencu komplementa prve efektorske sekvence;
pri čemu je svaka efektorska sekvenca najmanje 85% komplementarna predviđenom transkriptu cilјne sekvence i pri čemu najmanje jedna od efektorskih sekvenci sadrži bilo kojih 10 ili više susjednih nukleotida sekvence navedene u SEQ ID NO: 9.
2. Agens RNK interferencije usmjerene sa DNK (ddRNKi) za inhibiciju ekspresije jedne ili više cilјnih sekvenci u jednom ili u više gena virusa hepatitisa B (HBV), ddRNKi agens koji sadrži, u smjeru 5’ do 3’:
prvu efektorsku sekvencu dužine od najmanje 17 nukleotida;
sekvencu komplementa prve efektorske sekvence;
drugu efektorsku sekvencu dužine od najmanje 17 nukleotida; i
sekvencu komplementa druge efektorske sekvence;
pri čemu je svaka efektorska sekvenca najmanje 85% komplementarna predviđenom transkriptu cilјne sekvence i pri čemu najmanje jedna od efektorskih sekvenci sadrži bilo kojih 10 ili više susjednih nukleotida sekvence navedene u SEQ ID NO: 9.
3. Agens za ddRNKi prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, gdje najmanje jedna od efektorskih sekvenci sadrži bilo kojih 17 ili više susjednih nukleotida sekvence navedene u SEQ ID NO: 9.
4. Agens za ddRNKi prema bilo kojem od patentnih zahtjeva od 1 do 3, gdje efektorska sekvenca koja sadrži bilo kojih 10 ili više susjednih nukleotida sekvence nevedne u SEQ ID NO: 9 je sekvenca navedena u SEQ ID NO: 9.
5. Agens za ddRNKi prema bilo kojem od patentnih zahtjeva od 1 do 4, koji sadrži treću efektorsku sekvencu i sekvencu kojemplementa treće efektorske sekvence.
6. Agens za ddRNKi prema bilo kojem od patentnih zahtjeva od 1-5, gdje je najmanje jedna od drugih efektorskih sekvenci izabrana iz grupe koja se sastoji od bilo kojih 10 ili više susjednih nukleotida unutar sekvence navedene u bilo kojoj od SEQ ID NO: 1 do 8 ili 10 do 27.
7. Agens za ddRNKi prema patentnom zahtjevu 6, gdje najmanje jedna od drugih efektorskih sekvenci je sekvenca izabrana od sekvenci navedenih u SEQ ID NO: 1 do 8 ili 10 do 27.
8. Agens za ddRNKi prema patentnom zahtjevu 7, gdje najmanje jedna od drugih efektorskih sekvenci je sekvenca izabrana od sekvenci navedenih u SEQ ID NO: 3, 12, 13 i 23.
9. Ekspresijska kaseta za ekspresiju ddRNKi agensa prema bilo kojem od patentnih zahtjeva od 1 do 8, pri čemu ddRNKi ekspresijska kaseta sadrži:
jednu ili više promotorskih sekvenci;
jednu ili više DNK sekvenci koje kodiraju jednu ili više efektorskih sekvenci ddRNKi agensa prema bilo kojem od patentnih zahtjeva od 1 do 8;
jednu ili više DNK sekvenci koje kodiraju jednu ili više sekvenci efektorskog komplementa ddRNKi agensa prema bilo kojem od patentnih zahtjeva od 1 do 8;
jednu ili više terminatorskih sekvenci; i opcionalno
jednu ili više DNK sekvenci koje kodiraju sekvence petlјi; i opcionalno jednu ili više sekvenci pojačivača.
10. Ekspresijski konstrukt za ddRNKi agens koji sadrži ddRNKi ekspresijsku kasetu prema patentnom zahtjevu 9.
11. Agens za ddRNKi prema bilo kojem od patentnih zahtjeva od 1 do 8 ili ddRNKi ekspresijska kaseta prema patentnom zahtjevu 9 ili ddRNKi ekspresijski konstrukt prema patentnom zahtjevu 10, za upotrebu u liječenju akutne ili kronične HBV infekcije kod subjekta ili za upotrebu u smanjenju ozbilјnosti simptoma povezanih s HBV infekcijom kod subjekta.
12. Agens za ddRNKi prema bilo kojem od patentnih zahtjeva od 1 do 8 ili ddRNKi ekspresijska kaseta prema patentnom zahtjevu 9 ili ddRNKi ekspresijski konstrukt prema patentnom zahtjevu 10, za upotrebu u smanjenju virusnog opterećenja HBV-om kod subjekta.
13. Agens za ddRNKi prema bilo kojem od patentnih zahtjeva od 1 do 8 ili ddRNKi ekspresijska kaseta prema patentnom zahtjevu 9 ili ddRNKi ekspresijski konstrukt prema patentnom zahtjevu 10, za upotrebu u smanjenju zaraznosti HBV-a kod subjekta.
14. Agens za ddRNKi ili ddRNKi ekspresijska kaseta ili ddRNKi ekspresijski konstrukt za upotrebu prema bilo kojem od patentnih zahtjeva od 11 do 13, gdje ddRNKi agens ili ddRNKi ekspresijska kaseta ili ddRNKi ekspresijski konstrukt inhibira ekspresiju barem gena za HBV polimerazu.
15. Farmaceutski sastav koja sadrži ddRNKi agens prema bilo kojem od patentnih zahtjeva od 1 do 8 ili ddRNK ekspresijsku kasetu prema patentnom zahtjevu 9 ili ddRNKi ekspresijski konstrukt prema patentnom zahtjevu 10 i farmaceutski prihvatlјiv nosač ili razrjeđivač.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010522003.3A CN101979557B (zh) | 2010-10-28 | 2010-10-28 | 一种siRNA分子及其在抗病毒药物中的应用 |
| CN201010521975.0A CN101979555B (zh) | 2010-10-28 | 2010-10-28 | 一种小干扰rna分子及其应用 |
| CN201010522005.2A CN101979558B (zh) | 2010-10-28 | 2010-10-28 | 一种靶向乙型肝炎病毒基因的siRNA分子及其应用 |
| CN201010521962.3A CN101979554B (zh) | 2010-10-28 | 2010-10-28 | 一种干扰HBV基因的siRNA分子及其应用 |
| CN201010521990.5A CN101979556B (zh) | 2010-10-28 | 2010-10-28 | 一种siRNA靶向分子及其应用 |
| CN201010521948.3A CN101979553B (zh) | 2010-10-28 | 2010-10-28 | 一种干扰HBV基因的siRNA分子及其抗病毒应用 |
| CN201010521972.7A CN102021170B (zh) | 2010-10-28 | 2010-10-28 | 一种干扰乙型肝炎病毒基因的siRNA分子及其应用 |
| PCT/CN2011/071107 WO2012109798A1 (en) | 2011-02-18 | 2011-02-18 | Hbv treatment |
| EP16188642.9A EP3124610B1 (en) | 2010-10-28 | 2011-10-27 | Hbv treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190995T1 true HRP20190995T1 (hr) | 2019-08-09 |
Family
ID=45993174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190995TT HRP20190995T1 (hr) | 2010-10-28 | 2019-05-31 | LIJEČENJE HBV-a |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US9080174B2 (hr) |
| EP (2) | EP3124610B1 (hr) |
| KR (2) | KR101903778B1 (hr) |
| CN (1) | CN103370415B (hr) |
| AU (1) | AU2011320437B2 (hr) |
| BR (1) | BR112013010525A2 (hr) |
| CA (1) | CA2853613C (hr) |
| CY (1) | CY1121894T1 (hr) |
| DK (1) | DK3124610T3 (hr) |
| ES (1) | ES2730393T3 (hr) |
| HR (1) | HRP20190995T1 (hr) |
| HU (1) | HUE044426T2 (hr) |
| LT (1) | LT3124610T (hr) |
| PL (1) | PL3124610T3 (hr) |
| PT (1) | PT3124610T (hr) |
| RS (1) | RS58982B1 (hr) |
| RU (1) | RU2620966C2 (hr) |
| SI (1) | SI3124610T1 (hr) |
| TR (1) | TR201908127T4 (hr) |
| WO (1) | WO2012055362A1 (hr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3505528T1 (sl) | 2011-04-21 | 2021-04-30 | Glaxo Group Limited | Modulacija izražanja virusa hepatitisa B (HBV) |
| SG11201507496UA (en) | 2013-04-17 | 2015-11-27 | Pfizer | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| CN105002214B (zh) * | 2015-04-08 | 2018-07-17 | 许中伟 | 用于载体表达的复合多联gRNA和RNAi的表达框架 |
| CN107683336A (zh) * | 2015-05-06 | 2018-02-09 | 贝尼泰克生物制药有限公司 | 用于治疗乙型肝炎病毒(hbv)感染的试剂及其用途 |
| CA2991639A1 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
| RS61528B1 (sr) | 2016-03-14 | 2021-04-29 | Hoffmann La Roche | Oligonukleotidi za smanjenje ekspresije pd-l1 |
| RU2748806C2 (ru) * | 2016-05-05 | 2021-05-31 | Бенитек Байофарма Лимитед | Средства для лечения инфекции вируса гепатита в (hbv) и их применение |
| MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| CN108929870B (zh) * | 2017-05-19 | 2020-01-24 | 百奥迈科生物技术有限公司 | 抑制HBV的siRNA分子及其应用 |
| UA126931C2 (uk) | 2017-10-16 | 2023-02-22 | Ф. Хоффманн-Ля Рош Аг | МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B |
| CA3097544A1 (en) | 2018-04-05 | 2019-10-10 | F. Hoffmann-La Roche Ag | Use of fubp1 inhibitors for treating hepatitis b virus infection |
| MX2020013366A (es) | 2018-07-03 | 2021-03-09 | Hoffmann La Roche | Oligonucleotidos para modular la expresion de tau. |
| BR112021000538A2 (pt) | 2018-07-13 | 2021-04-06 | F. Hoffmann-La Roche Ag | Oligonucleotídeos para modular a expressão de rtel1 |
| WO2021122993A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of saraf inhibitors for treating hepatitis b virus infection |
| CN114901821A (zh) | 2019-12-19 | 2022-08-12 | 豪夫迈·罗氏有限公司 | Sept9抑制剂用于治疗乙型肝炎病毒感染的用途 |
| WO2021122921A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of cops3 inhibitors for treating hepatitis b virus infection |
| JP2023506550A (ja) | 2019-12-19 | 2023-02-16 | エフ． ホフマン－ラ ロシュ エージー． | Ｂ型肝炎ウイルス感染症を処置するためのｓｂｄｓ阻害剤の使用 |
| EP4200419A2 (en) | 2020-08-21 | 2023-06-28 | F. Hoffmann-La Roche AG | Use of a1cf inhibitors for treating hepatitis b virus infection |
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| NZ547283A (en) | 1998-03-20 | 2008-06-30 | Commw Scient Ind Res Org | Control of gene expression |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Ｒｎａ干渉の方法とｒｎａ干渉組成物 |
| US7919309B2 (en) | 2001-09-13 | 2011-04-05 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
| EP1572943B1 (en) | 2002-08-29 | 2015-04-22 | The Board of Trustees of The Leland S. Stanford Junior University | Circular nucleic acid vectors, and methods for making and using the same |
| US20050059044A1 (en) | 2003-06-03 | 2005-03-17 | Graham Michael Wayne | Double-stranded nucleic acid |
| WO2005087926A2 (en) | 2004-03-05 | 2005-09-22 | Benitec, Inc. | Multiple promoter expression cassettes for simultaneous delivery of rnai agents |
| EP1844145A2 (en) | 2005-02-03 | 2007-10-17 | Benitec, Inc. | Rnai expression constructs |
| US8008468B2 (en) | 2005-02-16 | 2011-08-30 | Benitec, Inc. | RNAi expression constructs with liver-specific enhancer/promoter |
| AR057252A1 (es) * | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
| WO2007120533A2 (en) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Minigene expression cassette |
| CN101684478B (zh) * | 2009-06-26 | 2012-02-29 | 武汉大学 | 一种串联表达小干扰rna重组慢病毒载体的构建方法 |
| CN101979556B (zh) * | 2010-10-28 | 2015-01-21 | 百奥迈科生物技术有限公司 | 一种siRNA靶向分子及其应用 |
-
2011
- 2011-10-27 KR KR1020137013563A patent/KR101903778B1/ko active IP Right Grant
- 2011-10-27 DK DK16188642.9T patent/DK3124610T3/da active
- 2011-10-27 HU HUE16188642 patent/HUE044426T2/hu unknown
- 2011-10-27 WO PCT/CN2011/081386 patent/WO2012055362A1/en active Application Filing
- 2011-10-27 TR TR2019/08127T patent/TR201908127T4/tr unknown
- 2011-10-27 RS RS20190704A patent/RS58982B1/sr unknown
- 2011-10-27 RU RU2013124422A patent/RU2620966C2/ru active
- 2011-10-27 KR KR1020187027763A patent/KR20180110186A/ko not_active Application Discontinuation
- 2011-10-27 PT PT16188642T patent/PT3124610T/pt unknown
- 2011-10-27 CA CA2853613A patent/CA2853613C/en active Active
- 2011-10-27 PL PL16188642T patent/PL3124610T3/pl unknown
- 2011-10-27 EP EP16188642.9A patent/EP3124610B1/en active Active
- 2011-10-27 AU AU2011320437A patent/AU2011320437B2/en not_active Ceased
- 2011-10-27 EP EP11835635.1A patent/EP2633051B1/en not_active Not-in-force
- 2011-10-27 US US13/882,124 patent/US9080174B2/en not_active Expired - Fee Related
- 2011-10-27 CN CN201180062884.8A patent/CN103370415B/zh not_active Expired - Fee Related
- 2011-10-27 SI SI201131733T patent/SI3124610T1/sl unknown
- 2011-10-27 LT LTEP16188642.9T patent/LT3124610T/lt unknown
- 2011-10-27 ES ES16188642T patent/ES2730393T3/es active Active
- 2011-10-27 BR BR112013010525A patent/BR112013010525A2/pt not_active Application Discontinuation
-
2015
- 2015-06-05 US US14/731,824 patent/US9410154B2/en not_active Expired - Fee Related
-
2019
- 2019-05-31 HR HRP20190995TT patent/HRP20190995T1/hr unknown
- 2019-06-03 CY CY20191100583T patent/CY1121894T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012055362A1 (en) | 2012-05-03 |
| BR112013010525A2 (pt) | 2016-08-02 |
| RU2013124422A (ru) | 2014-12-10 |
| PT3124610T (pt) | 2019-06-14 |
| CN103370415A (zh) | 2013-10-23 |
| KR20140071949A (ko) | 2014-06-12 |
| SI3124610T1 (sl) | 2019-08-30 |
| EP2633051A1 (en) | 2013-09-04 |
| ES2730393T3 (es) | 2019-11-11 |
| KR101903778B1 (ko) | 2018-10-04 |
| PL3124610T3 (pl) | 2019-09-30 |
| CY1121894T1 (el) | 2020-10-14 |
| RS58982B1 (sr) | 2019-08-30 |
| US20130296401A1 (en) | 2013-11-07 |
| EP3124610A1 (en) | 2017-02-01 |
| LT3124610T (lt) | 2019-08-12 |
| HUE044426T2 (hu) | 2019-10-28 |
| EP3124610B1 (en) | 2019-03-06 |
| DK3124610T3 (da) | 2019-06-11 |
| CN103370415B (zh) | 2017-05-31 |
| CA2853613A1 (en) | 2012-05-03 |
| AU2011320437A1 (en) | 2013-06-13 |
| US20150344885A1 (en) | 2015-12-03 |
| AU2011320437B2 (en) | 2017-03-16 |
| US9080174B2 (en) | 2015-07-14 |
| KR20180110186A (ko) | 2018-10-08 |
| EP2633051B1 (en) | 2016-09-14 |
| CA2853613C (en) | 2020-03-24 |
| EP2633051A4 (en) | 2014-04-23 |
| RU2620966C2 (ru) | 2017-05-30 |
| TR201908127T4 (tr) | 2019-06-21 |
| US9410154B2 (en) | 2016-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190995T1 (hr) | LIJEČENJE HBV-a | |
| JP2012136542A5 (hr) | ||
| JP2016116520A5 (hr) | ||
| JP2019519218A5 (hr) | ||
| JP2012528572A5 (hr) | ||
| JP2018512876A5 (hr) | ||
| JP2011512326A5 (hr) | ||
| WO2008116860A3 (en) | Dsrna compositions and methods for treating hpv infections | |
| JP2007527244A5 (hr) | ||
| JP2019519219A5 (hr) | ||
| JP2015523855A5 (hr) | ||
| JP2018519835A5 (hr) | ||
| JP2014513954A5 (hr) | ||
| JP2015518712A5 (hr) | ||
| JP2008535496A5 (hr) | ||
| JP2008525033A5 (hr) | ||
| WO2005014806A3 (en) | Conserved hbv and hcv sequences useful for gene silencing | |
| EA201201356A1 (ru) | Композиция для лечения респираторных синцитиальных вирусов | |
| JP2009035530A5 (hr) | ||
| JP2011521652A5 (hr) | ||
| WO2006069064A3 (en) | Conserved hbv and hcv sequences useful for gene silencing | |
| JP2008500817A5 (ja) | Ｄｎａウイルスのマイクロｒｎａ及びそれを阻害する医薬品 | |
| JP2012505657A5 (hr) | ||
| JPWO2021055811A5 (hr) | ||
| WO2010090857A3 (en) | Methods for amplifying hepatitis c virus nucleic acids |